Across rheumatic diseases

Factors associated with severity and mortality of COVID-19 in patients with connective tissue diseases and rheumatoid arthritis: A nation-wide, population-based analysis of the French national medico-administrative SNDS database

Joint Bone SpinePublished Retrospective cohort study

Authors' conclusion

In CTD patients with COVID-19, use of glucocorticoids, rituximab, and certain immunosuppressants was associated with severity and mortality, while TNF inhibitors and methotrexate were protective.

Study context

Population
Adult patients with Connective Tissue Diseases (CTDs) (RA, systemic lupus, Sjögren's disease, inflammatory myopathies, SSc), French nationwide claims and hospitalization database, 202075.5% female
Participants
329,276 patients
Outcome
Hospitalization, severe inpatient stays (ICU admission or in-hospital mortality) and in-hospital mortality with COVID-19
Follow-up
January 1st to December 31st, 2020
Methodological detailsnation-wide, population-based, claims and hospitalization database (SNDS)
  • Nation-wide
  • Population-based
  • Claims and hospitalization database (SNDS)

Main finding

As reported in the abstract

COVID-19 hospitalization, ICU admission and death · 2020
Hospitalized with COVID-19
3,389 (1.03%)
Required ICU admission
973 (0.29%)
Died
713 (0.22%)
Hospitalized, severe stay or died: predominantly male, older, with comorbidities
P<0.0001 for all
Higher risk of hospitalization, severe inpatient stay and death with GC, LEF, SSZ, mycophenolate derivatives and RTX
P<0.05 for all
TNFi associated with reduced hospitalizations and severe inpatient stays
P<0.05 for all
MTX use associated with decreased mortality
P<0.01

Observational data: associations, not effects.

Original publication

Factors associated with severity and mortality of COVID-19 in patients with connective tissue diseases and rheumatoid arthritis: A nation-wide, population-based analysis of the French national medico-administrative SNDS database. Joint Bone Spine. Published 17 November 2024. doi:10.1016/j.jbspin.2024.105818

Composed by AI from the published abstract and checked against it. How Briefs are made →

Get them every week

New studies on this topic in My Week and in your Monday e-mail.

We e-mail you a sign-in link and a code. No password, no spam.